Results from a clinical trial of a personalized mRNA vaccine for melanoma have generated largely positive online reactions. The vaccine, which was administered alongside immunotherapy, reduced the risk of cancer recurrence or death by 42 percent compared with standard treatment. Many commenters expressed optimism about mRNA technology’s potential to treat cancer and asked when the vaccine might become available and what other cancer vaccines are in development. Some commenters remained skeptical of mRNA technology, repeating false claims that mRNA vaccines alter DNA or have caused widespread deaths.
Recommendation
Recommendations: While the trial may not be directly relevant to all public health organizations, communicators may consider using the findings to educate audiences about how mRNA technology is being studied for cancer treatment and other applications beyond infectious disease prevention. Where relevant, existing mRNA vaccine materials may also be updated to reflect emerging research and address common questions about the technology.
Reading links: NBC news
Communication resources: Use these shareable social media graphics on mRNA vaccines
